Match!

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Published on Nov 4, 2008in Annals of Internal Medicine19.315
· DOI :10.7326/0003-4819-149-9-200811040-00003
Ralf Nass18
Estimated H-index: 18
,
Suzan S. Pezzoli22
Estimated H-index: 22
+ 7 AuthorsMichael O. Thorner71
Estimated H-index: 71
Sources
Abstract
Background: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to be demonstrated. Objective: To determine whether MK-677, an oral ghrelin mimetic, increases growth hormone secretion into the young-adult range without serious adverse effects, prevents the decline of fat-free mass, and decreases abdominal visceral fat in healthy older adults. Design: 2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial. Setting: General clinical research center study performed at a university hospital. Participants: 65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age. Intervention: Oral administration of MK-677, 25 mg, or placebo once daily. Measurements: Growth hormone and insulin-like growth factor I levels. Fat-free mass and abdominal visceral fat were the primary end points after 1 year of treatment. Other end points were body weight, fat mass, insulin sensitivity, lipid and cortisol levels, bone mineral density, limb lean and fat mass, isokinetic strength, function, and quality of life. All end points were assessed at baseline and every 6 months. Results: Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects. Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, -0.5 kg [95% Cl, -1.1 to 0.2 kg] vs. 1.1 kg [Cl, 0.7 to 1.5 kg], respectively; P < 0.001), as did body cell mass, as reflected by intracellular water (change, -1.0 kg [Cl, -2.1 to 0.2 kg] vs. 0.8 kg [Cl, -0.1 to 1.6 kg], respectively; P = 0.021). No significant differences were observed in abdominal visceral fat or total fat mass; however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P = 0.001). Body weight increased 0.8 kg (Cl, -0.3 to 1.8 kg) in the placebo group and 2.7 kg (Cl, 2.0 to 3.5 kg) in the MK-677 group (P = 0.003). Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased. The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. Low-density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [Cl, -0.27 to -0.01 mmol/L]; -5.4 mg/dL [Cl, -10.4 to -0.4 mg/ dL]; P = 0.026); no differences between groups were observed in total or high-density lipoprotein cholesterol levels. Cortisol levels increased 47 nmol/L (Cl, 28 to 71 nmol/L (1.7 μg/dL [Cl, 1.0 to 2.6 μg/dL]) in MK-677 recipients (P = 0.020). Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients. Increased fat-free mass did not result in changes in strength or function. Two-year exploratory analyses confirmed the 1-year results. Limitation: Study power (duration and participant number) was insufficient to evaluate functional end points in healthy elderly persons. Conclusion: Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.
Figures & Tables
  • References (45)
  • Citations (180)
📖 Papers frequently viewed together
200043.07Nature
3,280 Citations
199943.07Nature
6 Authors (Masayasu Kojima, ..., Kenji Kangawa)
6,476 Citations
107 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References45
Newest
#1M. Elbornsson (Sahlgrenska University Hospital)H-Index: 3
#2G. Götherström (Sahlgrenska University Hospital)H-Index: 6
Last. Johan SvenssonH-Index: 33
view all 6 authors...
There are few studies that have determined the effects of long-term GH replacement on bone mineral density (BMD) in GH-deficient (GHD) adults. In this study, the effects of 10 years of GH replacement on BMD were assessed in 87 GHD adults using dual energy X-ray absorptiometry (DEXA). The results show that GH replacement induced a sustained increase in BMD at all the skeletal sites measured. Introduction: Little is known of the effect of more than 5 years of GH replacement therapy on bone metabol...
102 CitationsSource
Background. Few studies have evaluated prospectively age-related body composition changes and their relationships with worsening disability in the elderly population. Methods. Ninety-seven women and 62 men aged 71.4 ± 2.2 and 71.6 ± 2.2 years, respectively, at baseline underwent dual-energy x-ray absorptiometry determinations at baseline and at 2- and 5.5-year follow-up intervals to measure total body and leg fat (FM) and total, appendicular, and leg fat-free mass (FFM). Height, weight, body mas...
98 CitationsSource
There is now a large body of evidence that weight loss in older persons not only increases mortality, but also increases the incidence of hip fracture, functional deterioration and institutionalization. Weight loss is a central component of frailty. There is evidence that it is not only muscle, but also fat loss that leads to these deleterious effects. The reasons why fat loss can be harmful in older persons are reviewed. There are four major causes of weight loss in older persons viz. anorexia,...
139 CitationsSource
#1David R. Thomas (SLU: Saint Louis University)H-Index: 35
Summary A loss of body weight or skeletal muscle mass is common in older persons and is a harbinger of poor outcome. Involuntary weight loss can be categorized into three primary etiologies of starvation, sarcopenia, and cachexia. Starvation results in a loss of body fat and non-fat mass due to inadequate intake of protein and energy. Sarcopenia is associated with a reduction in muscle mass and strength occurring with normal aging, associated with a reduction in motor unit number and atrophy of ...
330 CitationsSource
#2Keiji IidaH-Index: 24
Last. Michael O. ThornerH-Index: 71
view all 10 authors...
Phosphoinositide (PI) 3-kinase is involved in insulin-mediated effects on glucose uptake, lipid deposition, and adiponectin secretion from adipocytes. Genetic disruption of the p85α regulatory subunit of PI 3-kinase increases insulin sensitivity, whereas elevated p85α levels are associated with insulin resistance through PI 3-kinase–dependent and –independent mechanisms. Adipose tissue plays a critical role in the antagonistic effects of growth hormone (GH) on insulin actions on carbohydrate and...
115 CitationsSource
#1Hau Liu (Stanford University)H-Index: 12
#2Dena M. Bravata (Stanford University)H-Index: 32
Last. Andrew R. Hoffman (Stanford University)H-Index: 74
view all 7 authors...
Background: Human growth hormone (GH) is widely used as an antiaging therapy, although its use for this purpose has not been approved by the U.S. Food and Drug Administration and its distribution as an antiaging agent is illegal in the United States. Purpose: To evaluate the safety and efficacy of GH therapy in the healthy elderly. Data Sources: The authors searched MEDLINE and EMBASE databases for English-language studies published through 21 November 2005 by using such terms as growth hormone ...
243 CitationsSource
#1Barbara G. Tabachnick (CSUN: California State University, Northridge)H-Index: 23
#2Linda S. Fidell (CSUN: California State University, Northridge)H-Index: 11
8,074 Citations
#1Jeremy D. Walston (University of Pittsburgh)H-Index: 65
#2Evan C. Hadley (University of Pittsburgh)H-Index: 23
Last. Linda P. Fried (University of Pittsburgh)H-Index: 120
view all 9 authors...
Evolving definitions of frailty, and improved understanding of molecular and physiological declines in multiple systems that may increase vulnerability in frail, older adults has encouraged investigators from many disciplines to contribute to this emerging field of research. This article reports on the results of the 2004 American Geriatrics Society/National Institute on Aging conference on a Research Agenda on Frailty in Older Adults, which brought together a diverse group of clinical and basic...
927 CitationsSource
#1Analiza M. SilvaH-Index: 28
#2Jingsong WangH-Index: 67
Last. Stanley HeshkaH-Index: 40
view all 7 authors...
Aging is associated with the onset of chronic diseases that lead to pathological expansion of the extracellular water (ECW) compartment. Healthy aging, in the absence of disease, is also reportedly accompanied by a relative expansion of the ECW compartment, although the studies on which this observation is based are few in number, applied different ECW measurement methods, included small ethnically homogeneous subject samples, and failed to adjust ECW for non-age-related influencing factors. The...
16 CitationsSource
#1Roy G. Smith (BCM: Baylor College of Medicine)H-Index: 75
The GH secretagogues (GHS) were developed by reverse pharmacology. The objective was to develop small molecules with pharmacokinetics suitable for once-daily oral administration that would rejuvenate the GH/IGF-I axis. Neither the receptor nor the ligand that controlled pulse amplitude of hormone release was known; therefore, identification of lead structures was based on function. I reasoned that GH pulse amplitude could be increased by four possible mechanisms: 1) increasing GHRH release; 2) a...
128 CitationsSource
Cited By180
Newest
#1Michael Camilleri (Mayo Clinic)H-Index: 111
#2Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 52
view all 8 authors...
BACKGROUND: Relamorelin, a pentapeptide ghrelin receptor agonist, accelerated gastric emptying significantly and improved symptoms in adults with diabetic gastroparesis in phase 2 trials. AIM: To assess the safety and tolerability of relamorelin across phase 2 trials. METHODS: Safety assessments in patients aged 18-75 years (weight, adverse events [AEs] and laboratory tests) from two randomised, double-blind phase 2 trials (NCT01571297, NCT02357420; results published previously) were reviewed de...
Source
#1Aurel B. Leuchtmann (University of Basel)
#2Christoph Handschin (University of Basel)H-Index: 40
Abstract Sarcopenia, the age-related loss of skeletal muscle mass and function, increases the risk of developing chronic diseases in older individuals and is a strong predictor of disability and death. Because of the ongoing demographic transition, age-related muscle weakness is responsible for an alarming and increasing contribution to health care costs in Western countries. Exercise-based interventions are most successful in preventing the decline in skeletal muscle mass and in preserving or a...
Source
#1Emilio Molina-Molina (University of Bari)H-Index: 3
#2Gabriella Garruti (University of Bari)H-Index: 16
Last. PieroPortincasa (University of Bari)H-Index: 46
view all 7 authors...
Sufficient caloric intake is important to maintain the balanced health status, especially during the period of aging, as aging and sickness share paths. Maintaining adequate nutritional balance is the best preventive measure to counteract the risk of malnutrition. There are several causes for malnutrition in elderly people, and some techniques like anthropometric measurements, laboratory and clinical parameters could help to diagnose malnutrition in these patients. The use of a simple validated ...
Source
#1Ken Sugimoto (Osaka University)H-Index: 28
#2Hiromi Rakugi (Osaka University)H-Index: 70
Last. Hideki Fukuoka (Kyoto Prefectural University of Medicine)H-Index: 5
view all 12 authors...
Source
#1Junichi Ishida (GAU: University of Göttingen)H-Index: 10
#2Masakazu Saitoh (GAU: University of Göttingen)H-Index: 9
Last. Stephan von HaehlingH-Index: 2
view all 6 authors...
Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS-R), whose natural ligand is ghrelin, and agonists of the growth hormone-releasing hormone receptor (GHRH-R), to which the growth hormone-releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosisg of GH deficiency, which causes growth retardation...
Source
#1Seong Gak Jeon (Konyang University)H-Index: 5
#2Sang Bum Hong (Konyang University)H-Index: 1
Last. Minho Moon (Konyang University)H-Index: 23
view all 12 authors...
Abstract Ghrelin, which has many important physiological roles, such as stimulating food intake, regulating energy homeostasis, and releasing insulin, has recently been studied for its roles in a diverse range of neurological disorders. Despite the several functions of ghrelin in the central nervous system, whether it works as a therapeutic agent for neurological dysfunction has been unclear. Altered levels and various roles of ghrelin have been reported in Alzheimer’s disease (AD), which is cha...
1 CitationsSource
#1Gabriela Colon (FSU: Florida State University)H-Index: 1
#2Tatiana D. Saccon (UCF: University of Central Florida)H-Index: 2
Last. Michal M. Masternak (UCF: University of Central Florida)H-Index: 30
view all 14 authors...
Growth hormone (GH) is secreted by the anterior pituitary gland and regulates various metabolic processes throughout the body. GH and IGF-1 levels are markedly reduced in older humans, leading some to hypothesize GH supplementation could be a viable “anti-aging” therapy. However, there is still much debate over the benefits and risks of GH administration. While an early study of GH administration reported reduced adiposity and lipid levels and increased bone mineral density, subsequent studies f...
5 CitationsSource
#1Richard I. G. Holt (University of Southampton)H-Index: 43
#2Ken K. Y. Ho (Garvan Institute of Medical Research)H-Index: 60
GH is banned by the World Anti-Doping Agency as a performance-enhancing anabolic agent. Doping with GH likely began in the early 1980s and became more prevalent with the advent of recombinant technology well before any scientific evidence of benefit. The expectation that GH improves physical function stems from its anabolic and lipolytic properties. Athletic performance depends on muscle strength and the energy required to power muscle function. In recreational athletes, GH selectively improves ...
Source
#1Jürgen M. Bauer (Heidelberg University)H-Index: 25
Last. Curtis Cooper (University of Oxford)H-Index: 181
view all 24 authors...
The co-existence of impaired bone health (osteopenia/osteoporosis), reduced muscle mass and strength (sarcopenia), and increased adiposity (obesity) in middle-aged and older people has been identified in recent studies, leading to a proposal for the existence of “osteosarcopenic obesity” as a distinct entity. Evidence for the pathophysiological overlap of these conditions is mounting, although a causal relationship is yet to be established. Each component condition occurs frequently with increas...
1 CitationsSource
: Objective This paper reviews the main mechanisms, diagnostic criteria, treatment options and available data on sarcopenia in endocrine and non-endocrine disorders. The literature notes the presence of sarcopenia as a comorbid condition or a complication of another clinical situation and not a disease that only affects elderly patients. Method We performed a literature review, focusing on the following: mechanisms related to sarcopenia in elderly patients, and sarcopenia as it presents in the c...
Source